understanding cholesterol effects of adalimumab by new techniques was another goal of gelfand and mehta's study.
.
.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
"we were quite surprised to find there were no significant differences," says study author
.